Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced topline results from the Phase 2 SEQUOIA study of fazirsiran (TAK-999/ARO-AAT) for liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).
Patients receiving 25 mg, 100 mg, or 200 mg of fazirsiran who had baseline fibrosis (n=16) demonstrated a dose-dependent mean reduction in serum mutant alpha-1 antitrypsin protein (Z-AAT) concentration at week 48 of 74%, 89%, and 94%, respectively.
All three doses reduced total liver Z-AAT with a median reduction of 94%.
In addition, PAS-D globule burden, a histological measure of Z-AAT accumulation, was reduced from a baseline mean of 5.9 to a post-baseline mean of 2.3 at the postbaseline liver biopsy visit.
Improvement in portal inflammation was observed in 42% of patients, while only 7% showed worsening.
Lastly, 50% of patients achieved an improvement in fibrosis of at least one point by METAVIR stage.
In contrast, by week 48, patients receiving a placebo who had baseline fibrosis (n=9) saw no meaningful changes from baseline in serum Z-AAT, a 26% increase in liver Z-AAT, and no meaningful change in PAS-D globule burden.
No placebo patients experienced an improvement in portal inflammation.
44% experienced worsening, 22% of placebo patients experienced worsening, while 38% experienced an improvement in fibrosis at the postbaseline liver biopsy visit.
Fazirsiran has been well tolerated, with treatment-emergent adverse events reported to date generally well balanced between fazirsiran and placebo groups.
Price Action: ARWR shares are down 22.60% at $28.95 on the last check Monday.
See more from Benzinga
Viridian’s Thyroid Eye Disease Candidate Shows Promise At Lower Doses
Daré Bioscience Shares Move Higher Intravaginal Ring Shows Promise In Menopause Symptoms
Obama Says Republicans Are ‘Obsessed’ With 2 Things — One Of Them Is Trump
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Related Quotes
Sutro Biopharma Inc (NASDAQ: STRO) announced results from a Phase 1 dose-expansion study of STRO-002 (luvelta) and interim safety data from exploratory cohort C of advanced ovarian cancer treated at the higher dose of luvelta (5.2mg/kg), along with prophylactic pegfilgrastim. Results demonstrated that luvelta provided substantial clinical benefit, with a 37.5% overall response rate (ORR), a median duration of response (median DOR) of 5.5 months, and median progression-free survival (median PFS)
The board of Cracker Barrel Old Country Store, Inc. ( NASDAQ:CBRL ) has announced that it will pay a dividend of $1.30…
Investors trying to capitalize on higher interest rates and the deep selloff in big technology stocks such as Amazon and Nvidia are stoking a flurry of activity in the options market.
Multiple insiders secured a larger position in Amyris, Inc. ( NASDAQ:AMRS ) shares over the last 12 months. This is…
Instil Bio Inc (NASDAQ: TIL) has resumed its Phase 1 clinical trial of ITIL-306 for non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC). With the resumption of the ITIL-306 Phase 1 study, the company plans to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023. The trial was resumed after implementing additional quality safeguards designed to further protect the manufacturing process from potential c
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
Voyager Therapeutics Inc., the gene therapy startup led by erstwhile Biogen Inc. executive Al Sandrock, has a new deal with a San Diego biotech that's worth up to $4.2 billion.
The SPDR S&P Biotech ETF is down 20% over the past year. In fact, BioMarin Pharmaceuticals (NASDAQ: BMRN) and Novo Nordisk (NYSE: NVO) are at their highest levels in a year. The company was founded in 1997 to develop treatments for extremely rare genetic diseases.
The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money.
You can't blame Biogen (NASDAQ: BIIB) investors if they feel a sense of déjà vu. The company, along with its partner, Japanese drugmaker Eisai (OTC: ESALY), received U.S. Food and Drug Administration (FDA) approval for Alzheimer's disease drug Leqembi (lecanemab-irmb) last week. Biogen has been in this position before.
Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.
Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.
Robert Califf acknowledged the agency made mistakes when it failed to properly document interactions with the company.
Covaxin is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades. “Covaxin, an inactivated virus vaccine adjuvanted with TLR7/8 agonist, has been demonstrated in clinical trials to generate a broader immune response against the whole virus covering important antigens such as S-protein, RBD, and N-protein; whereas currently approved vaccines in the U.S. target only S-protein antigen,” the company said in a statement.
A promising Alzheimer's drug is now getting fast-tracked by the FDA. Dr. Paul E. Schulz, the leading neurologist with UTHealth Houston and the McGovern School of Medicine, explains the benefits of Leqembi.
Biotech companies are trying to get in front of investors and potential partners — and regulators — with news ahead of the big J.P. Morgan Healthcare Conference in San Francisco.
After years of ups and downs, Novan is seeking federal approval for its lead product to treat a viral skin infection.
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. Paxlovid, an oral medicine developed by New York-based drugmaker Pfizer, has been widely sought after in China since the country began phasing out its “zero-COVID” restrictions and a surge of infections started sweeping through the country. A drug must be included on the reimbursement list to be covered by the national insurance scheme.
The content creator and model, 27, opened up about her doctor prescribing the medication, and how it eventually made her binge eating worse
